Clinical Trial Update: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A pediatric Phase 1/2 study is evaluating Onivyde (liposomal irinotecan) in combination with talazoparib or temozolomide in children with recurrent solid tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Solid Tumor

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)
• Talzenna (talazoparib)
• Temodar (Temozolomide)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1, Phase 2 | Status: RECRUITING